A phase 3b, randomized, double blind, controlled study evaluating the efficacy and safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis subjects, homozygous for F508del mutation - VX18-445-109

Status	Finished
Effective start/end date	1/10/19 → 30/09/21

Project Details